Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.


Journal Article (Review)

Randomized controlled trials (RCTs) have suggested a potential advantage of dose-dense chemotherapy in improving disease-free and overall survival in patients with certain malignancies. This systematic review summarizes the literature on the efficacy of dose-dense chemotherapy across various cancers (breast cancer, non-Hodgkin lymphoma [NHL], and non-small cell lung cancer) and chemotherapy regimens. Among the 17 trials identified, few reported statistically significant differences between dose-dense and standard chemotherapy, and most were small with limited statistical power. Statistically significant differences in overall survival favoring dose-dense schedules were apparent among large RCTs in potentially curative settings such as early-stage breast cancer and NHL. Clinical and treatment heterogeneity demonstrated the flexibility of the dose-dense paradigm but also precluded quantitative meta-analysis of results. Further study of dose-dense schedules based on large RCTs is needed to demonstrate the consistency and generalizability of these findings.

Full Text

Duke Authors

Cited Authors

  • Lyman, GH; Barron, RL; Natoli, JL; Miller, RM

Published Date

  • March 2012

Published In

Volume / Issue

  • 81 / 3

Start / End Page

  • 296 - 308

PubMed ID

  • 21636289

Pubmed Central ID

  • 21636289

Electronic International Standard Serial Number (EISSN)

  • 1879-0461

Digital Object Identifier (DOI)

  • 10.1016/j.critrevonc.2011.04.010


  • eng

Conference Location

  • Netherlands